Sex-Related Differences in Risk Factors Associated With Nonhealing or Recurrence of Hyperthyroidism in Patients With Graves' Disease Treated With Radioactive Iodine
- PMID: 40568628
- PMCID: PMC12185363
- DOI: 10.1002/hcs2.70021
Sex-Related Differences in Risk Factors Associated With Nonhealing or Recurrence of Hyperthyroidism in Patients With Graves' Disease Treated With Radioactive Iodine
Abstract
Background: To evaluate sex-related differences in the risk factors associated with nonhealing or recurrence of hyperthyroidism (NHRH) in patients with Graves' disease (GD) treated with radioactive iodine.
Methods: In total, 285 patients were enrolled. Data on radioactive iodine (RAI) dosage, ultrasound indexes of the thyroid, and other clinical factors were collected. Patients were divided into NHRH and non-NHRH (hypothyroidism or euthyroidism) groups based on treatment outcomes. Univariate and multivariate weighted logistic regression analyses were used to identify factors associated with NHRH. Sex-specific analyses of these risk factors were also conducted.
Results: There were no significant differences between the two groups in terms of sex, thyroid shear wave elastography velocity values, or pretreatment serum free thyroxine (FT4) levels. Thyroid volume and age were independently associated with NHRH, with the odds of NHRH gradually decreasing as age increased. In subgroup analyses, both age and thyroid volume were independent risk factors for NHRH in female patients (p < 0.05), while in male patients, only FT4 was independently associated with NHRH (p < 0.05).
Conclusions: In patients of different sexes, the influence of thyroid volume, age, and FT4 on treatment outcomes exhibits distinct patterns.
© 2025 The Author(s). Health Care Science published by John Wiley & Sons Ltd on behalf of Tsinghua University Press.
Conflict of interest statement
Xianbo Zuo is a member of the Health Care Science Editorial Board. To minimize bias, he was excluded from all editorial decision‐making related to the acceptance of this article for publication. The remaining authors declare no conflicts of interest.
Figures
Similar articles
-
Radioiodine therapy versus antithyroid medications for Graves' disease.Cochrane Database Syst Rev. 2016 Feb 18;2(2):CD010094. doi: 10.1002/14651858.CD010094.pub2. Cochrane Database Syst Rev. 2016. PMID: 26891370 Free PMC article.
-
Antithyroid drug regimen for treating Graves' hyperthyroidism.Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003420. doi: 10.1002/14651858.CD003420.pub3. Cochrane Database Syst Rev. 2005. Update in: Cochrane Database Syst Rev. 2010 Jan 20;(1):CD003420. doi: 10.1002/14651858.CD003420.pub4. PMID: 15846664 Updated.
-
Iodine supplementation for women during the preconception, pregnancy and postpartum period.Cochrane Database Syst Rev. 2017 Mar 5;3(3):CD011761. doi: 10.1002/14651858.CD011761.pub2. Cochrane Database Syst Rev. 2017. PMID: 28260263 Free PMC article.
-
Unilateral Graves' disease: a case report with concomitant thyroid cancer and systematic review of literature.Minerva Surg. 2025 Jun;80(3):274-281. doi: 10.23736/S2724-5691.25.10685-0. Epub 2025 May 22. Minerva Surg. 2025. PMID: 40401585
-
Antithyroid drug regimen for treating Graves' hyperthyroidism.Cochrane Database Syst Rev. 2004;(2):CD003420. doi: 10.1002/14651858.CD003420.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003420. doi: 10.1002/14651858.CD003420.pub3. PMID: 15106202 Updated.
References
LinkOut - more resources
Full Text Sources